EU Approves AUCATZYL CAR T Therapy for Adult B-ALL

Published on: Autolus Therapeutics

The European Commission has granted marketing authorization for AUCATZYL (obecabtagene autoleucel) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). Approval was based on the FELIX trial, which showed a 76.6% complete response rate with durable outcomes and manageable toxicity. The therapy is already approved in the U.S. and U.K., marking a significant expansion of access in Europe.

👉 Read the full article: Autolus CAR T Therapy AUCATZYL Granted European Approval

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.